To our knowledge, this is the first phase 3 study supporting 12-week neoadjuvant treatment with a HER2-directed small-molecule TKI plus trastuzumab and chemotherapy in breast cancer patients. The gene discussed is ERBB2; the disease is breast carcinoma.